NOC

Northrop is a high-return, secularly-supported defense prime trading at a reasonable price, but its profitability has reset to a structurally lower level that limits the case for aggressive buying. FY2025 revenue grew to $42.0B (+2.2%), the fifth straight year of growth (up from $35.7B in 2021), yet net income was essentially flat at $4.18B (+0.2%) and operating margin sits at just 10.8%. The five-year net-income history tells the real story: $7.00B in 2021 collapsing to $2.06B in 2023 before recovering to ~$4.18B — a vivid demonstration of the fixed-price program risk management flags via the Nunn-McCurdy Act in its Risk Factors (programs like B-21 can force charges and even restructure/termination if cost thresholds are breached). EPS of $29.08 (+2.6%) is growing faster than net income only because the share count fell 2.0% on $1.62B of buybacks, not because the underlying business is re-rating higher.

On quality, the numbers are genuinely good where it counts: ROE of 25.1%, operating cash flow of $4.76B (+8.4%) against capex down 17.9% to $1.45B (implying ~$3.3B free cash flow), and a manageable balance sheet (equity $16.7B vs. ~$15.7B total debt, $4.4B cash, liabilities/equity 2.08x). Capital return is healthy — $1.62B buybacks plus $1.29B dividends (+9.0%). The MD&A frames a supportive demand backdrop: a 'global security environment of heightened tensions,' explicit pull from Ukraine, the Middle East and the Western Pacific, and strength in space, C4ISR, missile defense and strategic deterrence — all of which underpin a multi-year, long-horizon order book.